Allergic rhinitis — the sneezing, congestion, and itching triggered by allergen exposure — is commonly managed with antihistamines, nasal steroids, and allergen avoidance. Intranasal phototherapy, sometimes called rhinophototherapy, offers a different mechanism entirely: it uses targeted light energy delivered directly inside the nasal cavity to modulate the local immune response responsible for allergic symptoms. This article explains how the technology works and what a typical treatment course looks like.
What Is Intranasal Phototherapy?
Intranasal phototherapy involves delivering a specific combination of light wavelengths — typically narrow-band ultraviolet B (UVB), visible light, and infrared wavelengths — directly to the nasal mucosa using a specialized device. Unlike systemic medications that act throughout the body, this localized approach targets the tissue where allergic inflammation actually occurs. The treatment is generally classified as non-pharmacological, meaning it does not rely on drug absorption or systemic hormonal effects to achieve its intended result.
How Does Light Exposure Affect Allergic Symptoms?
The proposed mechanism behind intranasal phototherapy involves the effect of these specific wavelengths on immune cells present in the nasal mucosa, including mast cells, T-lymphocytes, and eosinophils — all of which play a role in the allergic cascade that produces symptoms such as histamine release, swelling, and mucus production. By acting on these cell populations locally, the therapy is intended to help limit histamine release and reduce the downstream inflammatory response that produces the sneezing, itching, and congestion characteristic of allergic rhinitis.
What Does a Typical Treatment Session Involve?
Sessions with intranasal phototherapy devices are generally brief, commonly around five minutes per treatment, and are typically administered in a series over a defined treatment course rather than as a single application. Patients commonly report no heat sensation during treatment, since the therapy relies on specific light wavelengths rather than thermal energy to achieve its effect. Because the treatment is localized and non-invasive, it is generally well tolerated and does not require anesthesia or sedation.
The INVAMED Voltran Phototherapy System
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Who Might Consider This Approach?
Intranasal phototherapy may be of interest to patients with seasonal or perennial allergic rhinitis who prefer to limit or supplement medication use, or who have not achieved adequate symptom control with standard pharmacological approaches alone. As with any allergic rhinitis treatment, individual response varies, and a qualified physician determines suitability based on symptom pattern, allergy triggers, and overall treatment history.
Does intranasal phototherapy carry the same risks as UV skin exposure?
The therapy uses controlled, narrow-band wavelengths delivered locally within the nasal cavity under defined treatment parameters, which differs from unprotected broad-spectrum UV exposure to skin. Any concerns about cumulative light exposure should be discussed with the prescribing clinician, who can reference the device's Instructions for Use for guidance on treatment limits.